Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.
Sonoma Pharmaceuticals, Inc. (SNOA) delivers innovative healthcare solutions through its patented Microcyn® technology, specializing in stabilized hypochlorous acid (HOCl) products for wound care, dermatology, and animal health. This page provides a centralized resource for tracking the company’s latest developments, regulatory milestones, and strategic initiatives.
Access timely updates on FDA clearances, clinical study results, and product launches that demonstrate SNOA’s commitment to non-toxic, evidence-based therapies. Investors and healthcare professionals will find verified information about:
• New product approvals across global markets
• Partnership announcements with medical distributors
• Financial performance and growth strategies
• Research breakthroughs in HOCl applications
All content is curated to meet strict accuracy standards, with direct links to official press releases and validated third-party analyses. Bookmark this page for efficient monitoring of SNOA’s progress in advancing biocompatible wound care and antimicrobial solutions.
Sonoma Pharmaceuticals (Nasdaq:SNOA), a global healthcare leader developing Microcyn® technology based stabilized hypochlorous acid (HOCl) products, has announced its participation in two upcoming investor conferences:
1. Danisavage Financial Strategies Virtual 1x1 Investor Conference on October 24 at 2:00pm ET. CEO Amy Trombly and CFO Jerry Dvonch will be available for one-on-one meetings.
2. LD Micro Main Event XVII on October 29 at 1:30am PT at the Luxe Sunset Blvd Hotel in Los Angeles, CA. The presentation will be webcast live, and one-on-one meetings will be available on October 29-30, 2024.
These conferences provide opportunities for investors to learn more about Sonoma's wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has successfully regained compliance with Nasdaq's minimum bid price rule, avoiding potential delisting. The company, known for its patented Microcyn technology based on stabilized hypochlorous acid (HOCl), implemented a 1-for-20 reverse stock split on August 30, 2024. This action was taken in response to a non-compliance notice received on September 22, 2023, when SNOA's stock price fell below the required $1.00 per share minimum.
Following the reverse split, Sonoma's stock price maintained the required minimum for 10 consecutive business days, satisfying Nasdaq's compliance criteria. The company received formal confirmation from Nasdaq that it has regained compliance, and the matter is now closed. This development ensures Sonoma's continued listing on the Nasdaq Capital Market, maintaining its visibility and access to capital markets.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has received a new FDA 510(k) clearance for its Microcyn technology-based solution, expanding its over-the-counter (OTC) indications. The clearance allows for OTC management of minor skin abrasions, lacerations, and irritations on the face, eyelid, and eyelashes. This development strengthens Sonoma's position in the hypochlorous acid (HOCl) industry, particularly in eye care claims.
The company can now market its OTC dermatology products more broadly, targeting facial applications. Sonoma has also demonstrated safety, efficacy, and stability for a 2-ounce product size, opening up new packaging opportunities for consumer-friendly formats. CEO Amy Trombly emphasized that this clearance validates Sonoma's proprietary technology and expertise in HOCl, developed over two decades.
Sonoma Pharmaceuticals (NASDAQ:SNOA) and EMC Pharma have announced a co-marketing agreement to launch and sell an expanded prescription and OTC eye care product line. The collaboration includes:
1. EMC Pharma gaining rights to sell OTC Ocucyn
2. Sonoma gaining rights to sell prescription Acuicyn
3. Introduction of new design and packaging for Ocucyn
4. Presentation of the expanded product line at the American Academy of Ophthalmology's annual meeting in Chicago, October 18-21, 2024
Both products are based on Sonoma's patented Microcyn technology using stabilized hypochlorous acid (HOCl). This partnership aims to increase sales of both OTC and prescription eye care products by coordinating marketing efforts and expanding market reach.
Sonoma Pharmaceuticals (NASDAQ:SNOA) announced a 1-for-20 reverse split of its outstanding common stock, effective August 29, 2024, at 5:00 pm EDT. Trading on the adjusted basis will begin on August 30, 2024. This move aims to maintain the company's Nasdaq Capital Market listing by meeting the $1.00 minimum bid price requirement before September 16, 2024.
Key points:
- Common stock will reduce from ~20 million to ~1 million shares
- Authorized shares will increase from 24 million to 50 million
- No fractional shares will be issued; cash will be given in lieu
- Proportional adjustments to stock options and equity-compensation plans
- New CUSIP number will be issued
CEO Amy Trombly emphasized the importance of maintaining Nasdaq listing for business confidence and opportunities.
Sonoma Pharmaceuticals (Nasdaq: SNOA) and MicroSafe Group announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer. The product, manufactured by Sonoma using its patented Microcyn® technology, is now approved for use against Candida auris (C. auris) and Clostridium difficile (C. diff) with a 10-minute kill time.
Previously, Nanocyn® was approved with a 15-second kill time against SARS-CoV-2 and a 30-second kill time against Norovirus, Influenza A (H1N1), and bacteria like MRSA. The U.S. EPA has also approved Nanocyn® as an effective disinfectant against various pathogens. This extended approval highlights Nanocyn®'s broad-spectrum efficacy and its potential to enhance patient safety in healthcare settings.
Sonoma Pharmaceuticals (Nasdaq: SNOA) has announced a distribution agreement with a leading global healthcare distributor for its wound care products in the United States. The partnership will leverage the distributor's extensive network of hospital systems and healthcare channels to expand Sonoma's wound care business across the country.
Sonoma's products are based on their patented Microcyn® technology, which uses stabilized hypochlorous acid (HOCl) for various applications including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care. CEO Amy Trombly described the partnership as a "huge step forward" for the company's U.S. wound care business expansion.
Additional details about the agreement can be found in Sonoma's Current Report on Form 8-K filed with the SEC on August 21, 2024.
Sonoma Pharmaceuticals (NASDAQ: SNOA) reported financial results for Q1 FY2025 ended June 30, 2024. Key highlights include:
- European revenues increased 20% year-over-year
- Gross margin improved to 39% from 35% in the same period last year
- Net loss decreased by 19% compared to Q1 FY2024
- Total revenues remained flat at $3.4 million
- Operating expenses were nearly flat year-over-year at $2.5 million
- EBITDA loss remained stable at $1.0 million
- Cash and cash equivalents stood at $2.6 million as of June 30, 2024
The company expanded its product offerings and partnerships, including a new distribution agreement in Ukraine and increased presence in U.S. retail stores for its animal health care products.
Sonoma Pharmaceuticals (NASDAQ:SNOA) celebrates its 20th anniversary of selling wound care products in Europe. The company, known for its patented Microcyn® technology, announced a new partnership with Smart Healthcare Company (SHC) s.r.o. to distribute its Microdacyn60® wound care products in Ukraine. SHC, based in Slovakia, will collaborate with DANA MC, a major medical supplier in Ukraine. The Microdacyn60 solution and hydrogel, based on hypochlorous acid, aid in pain relief, irritation reduction, and wound healing by eliminating bacteria, fungi, and viruses without damaging healthy tissue. CEO Amy Trombly expressed pride in the milestone and the opportunity to address significant healthcare needs in Ukraine.
Sonoma Pharmaceuticals (Nasdaq: SNOA) reported a 14% increase in Q4 2024 revenues to $3.4 million, driven by rising product sales across all territories except 'Rest of the World'. Gross profit margin improved by 3% year-over-year to 32%. Despite a 24% rise in operating expenses due to increased R&D, net loss decreased by 18% to $1.1 million. For FY 2024, revenues dropped 4.5% to $12.7 million due to lower service revenue but gross profit margin increased to 37%. Net loss for the year improved by 6% to $4.8 million. CEO Amy Trombly highlighted product innovation and market expansion as key growth drivers.
